Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 11/12/2024 GMT			5-day change	1st Jan Change
18.90 ^SEK	-5.50%		-14.09%	-47.21%

11-13	Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
10-16	Guard Therapeutics Starts Mid-stage Study for Kidney Therapy	MT

Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 21, 2024 at 07:30 am

Guard Therapeutics International AB (publ) reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was SEK 17.1 million compared to SEK 40.49 million a year ago. Basic loss per share from continuing operations was SEK 1.7 compared to SEK 5.33 a year ago.

Latest news about Guard Therapeutics International AB

Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-13	CI
Guard Therapeutics Starts Mid-stage Study for Kidney Therapy	10-16	MT
Guard Therapeutics Announces First Patient in Europe Dosed in the Clinical Phase 2b POINTER Study	10-16	CI
First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER	08-29	CI
Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study	08-27	MT
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-22	CI
Guard Therapeutics Receives Regulatory EU Approvals to Include Patients in its Phase 2b Study POInter	08-08	CI
Guard Therapeutics Announces Scientific Journal American Journal of Physiology ? Renal Physiology Publishes Article Summarizing Important Preclinical Results of Its Clinical Drug Candidate RMC-035	05-27	CI
Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Guard Therapeutics International AB announced that it expects to receive SEK 59.99074 million in funding from Swedbank Robur Fonder AB, Industrifonden, Strand Kapitalforvaltning AB and another investor	05-07	CI
Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER	04-15	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-21	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-21	CI
Guard Therapeutics Presents Development Strategy and New Preclinical Results at R&D Update	01-31	CI
Guard Therapeutics - Yesterdays presentation of a research update	01-31	FW
US FDA Gives Positive Feedback on Guard Therapeutics’ RMC-035 Development Plan; Stock Plunges	01-15	MT
Guard Therapeutics International AB Announces Fda Provides Positive Feedback to Guard Therapeutics Regarding the Continued Development Plan for RMC-035	01-15	CI
Guard Therapeutics International AB Appoints Nomination Committee for 2024	12-07	CI
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Guard Therapeutics International AB Provides More Information on the Development Strategy for RMC-035	28/09/23	CI
Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 and Advances Clinical Development Program	19/09/23	CI
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Guard Therapeutics International AB Announces Completion of Clinical Phase 2 Study AKITA	14/07/23	CI
Guard Therapeutics Announces the Full Results from the Phase 1B Clinical Study of the Investigational Drug RMC-035 in Patients Undergoing Kidney Transplantation	14/06/23	CI
Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI

Chart Guard Therapeutics International AB

Duration

Period

Chart Guard Therapeutics International AB

GUARD: Dynamic Chart

Company Profile

A1M Pharma AB is a Sweden-based company, which is active within the healthcare sector. The Company conducts development and commercialization of treatment and diagnostics based on the alpha-1-microglobulin (A1M) protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic uses, such as alleviation of autoimmune diseases and stroke treatment. The Company works with the protein and conducts research at the Biomedical Center in Lund University, Sweden. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries.

Employees

Sector

Biotechnology & Medical Research

Calendar

19/02/2025 - Q4 2024 Earnings Release

More about the company